Andrew W. Mulcahy

Photo of Andrew Mulcahy
Policy Researcher; Associate Research Department Director, Economics, Sociology, and Statistics Department; Faculty Member, Pardee RAND Graduate School
Washington Office


Ph.D. in health care management and economics, The Wharton School; M.P.P. in health policy, The Johns Hopkins University; A.B. in molecular biology and public policy, Princeton University


Andrew Mulcahy is a policy researcher and associate director of the Economics, Sociology, and Statistics Department at the RAND Corporation; he is also a member of the Pardee RAND Graduate School faculty.

His key research areas are prescription drugs, payment for health care services and drugs, and policy evaluation in general and particularly evaluation of Affordable Care Act (ACA) provisions. He routinely uses large-scale health care claims and transactional data in his research.

Mulcahy leads projects using claims data to evaluate components of the ACA including the dependent coverage, coverage expansion, and Medicaid primary care payment increase provisions. In the area of payment, Mulcahy's recent research focuses on the accurate valuation of services under the Resource-Based Relative Value Scale system used by Medicare and many other payers to pay practitioners. In prescription drugs, Mulcahy is the lead author on a set of RAND Perspectives outlining key policy issues around the 340B Drug Discount Program and biosimilars.

Mulcahy's portfolio also includes analyses of medical care in California's workers' compensation system and an assessment of the U.S. blood system. More broadly, Mulcahy's research at RAND has touched on policy issues around specialty drugs, value in health care, and incentives for innovation in health.

Mulcahy earned his Ph.D. from the University of Pennsylvania's Wharton School Health Care Management and Economics program, his M.P.P. at the Johns Hopkins University with a concentration in health policy, and his A.B. in molecular biology and public policy at Princeton University.


  • White prescription pills on a U.S. $100 bill, photo by Stuart Ritchie/Getty Images

    Price-Fixing Case Reveals Vulnerability of Generic Drug Policies

    A massive lawsuit filed by 44 states accuses 20 major drug makers of colluding to inflate prices on more than 100 generic drugs, including HIV, cancer, and depression treatments. If these allegations are true, then this isn't just a violation of antitrust law. It's a betrayal of the policies that created and defended the entire generic drug industry.

    Jul 15, 2019 The Health Care Blog

  • A woman is wheeled through an emergency department on a gurney.

    Covering Emergency Care for Young Adults: Is the ACA Doing Its Job?

    The dependent coverage provision of the Affordable Care Act is working as intended, say Andrew Mulcahy and Katherine Harris. In 2011, it spared individuals and hospitals from $147 million in emergency room costs.

    Jun 5, 2013